| Cat. No. |
Product Name |
CAS No. |
Information |
| GY02863 |
Ombrabulin
|
181816-48-8 |
A novel combretastatin A-4 derivative and tubulin polymerization inhibitor that strongly stanches tumour blood flows and inhibits growth of tumours developing in various tissues and organ; a vascular-disrupting agent under clinical investigation combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. |
| GY10238 |
6-MOMIPP
|
1961272-45-6 |
6-MOMIPP is a novel microtubule disruptor that targets the colchicine binding site on β-tubulin, induces mitotic arrest, caspase activation and loss of cell viability of U251 glioblastoma in vitro; demonstrates broad activity against the viability of multiple glioblastoma, melanoma and lung carcinoma cell lines; effectively inhibits growth of subcutaneous and intracerebral tumors without causing general toxicity in mice bearing human U251 glioblastoma xenografts . |
| GY10297 |
CCB02
|
2100864-57-9 |
CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin; does not inhibits a panel of cell cycle- and centrosome-related kinases; impairs proliferation of cells with centrosome amplification, activates extra centrosomes to nucleate enhanced numbers of microtubules prior to mitosis, causes cells to undergo centrosome de-clustering, prolonged multipolar mitosis, and cell death; demonstrates broad anti-invasive activity in various cancer models, including tyrosine kinase inhibitor (TKI)-resistant EGFR-mutant NSCLC. |
| GY10340 |
ATM-3507
|
1861449-70-8 |
ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM; shows cancer cell cytotoxicity comparable with the first-in-class tool compound TR100, also shows a strong synergistic effect when TR100 or ATM-3507 were combined with antimicrotubule agents in both in vitro and in vivo neuroblastoma models. |
| GY10341 |
TR-100
|
1128165-86-5 |
TR-100 (TR100) is a specific anti-tropomyosin compound that disrupts the actin cytoskeleton via targeting of Tpm3.1-containing actin filaments; perturbs Tpm3.1-regulated actin filament depolymerisation from the barbed end without affecting the capacity of Tpm3.1 to regulate barbed end actin elongation or bind F-actin; TR-100 (TR100) is effective in vitro and in vivo in reducing tumor cell growth in neuroblastoma and melanoma models. |
| GY10502 |
Avanbulin
|
798577-91-0 |
Avanbulin (BAL27862, BAL-27862) is a novel microtubule-destabilizing agent that potently inhibits tubulin assembly at 37¡ãC with IC50 of 1.4 uM in tubulin-binding assays; potentli bindis to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissociation constant of 244¡À30 nM, BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers; inhibits tumor cell proliferation through activation of the spindle assembly checkpoint, inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells both in vitro and in vivo.
|
| GY06912 |
VERU-111
|
1332881-26-1 |
VERU-111 (VERU111) is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities; inhibits cell viability of human melanoma cell lines (A375, M14, and RPMI7951) with IC50 of 5-10 nM. |
| GY06726 |
MP-HJ-1b
|
2310293-81-1 |
MP-HJ-1b is a novel potent inhibitor of microtubule and tumor cell growth, binds the colchicine pocket at the intra-dimer interface, depolymerizes microtubules and affects spindle formation; shows activities against a panel of more than 1000 human cancer cell lines with a wide variety of tissue origins, also induces the spike-like conformation of microtubules in vitro and in vivo, which is different from typical microtubule modulators; exhibits an interesting property of general cytotoxicity instead of Ras-mutant-specific killing (A549 KRAS-G12S, IC50=0.04 uM); MPHJ-1b displayed favorable pharmacological properties for overcoming tumor MDR both in vitro and in vivo. |
| GY06724 |
VERU-111 analogue 13f
|
2250081-53-7 |
VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities; inhibits cell viability of human melanoma cell lines (A375, M14, and RPMI7951) with IC50 of 1-3 nM; VERU-111 analogue 13f is significantly more potent than VERU-111, exhibits a strong inhibitory effect on tumor growth in vivo. |
| GY01945 |
Cephalomannine
|
71610-00-9 |
A taxol derivative with antitumor, antiproliferative properties. |
$ USD
Select Your Country or Region
